Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
23h
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...
Fintel on MSN3d
Morgan Stanley Downgrades Third Harmonic Bio (THRD)Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...
American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...
Morgan Stanley downgraded Third Harmonic Bio (THRD) to Equal Weight from Overweight with a price target of $5, down from $20, after the company ...
Lipella Pharmaceuticals LIPO stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. IN8bio INAB shares increased by ...
As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 ...
The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...
1 Day THRD 2.88% DJIA 0.38% Russell 2K 1.07% Health Care/Life Sciences 0.19% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback